These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29929486)

  • 21. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
    Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
    Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Matrix Metalloproteinases -7, -8 and -9 and TIMP -1 with Disease Severity in Acute Pancreatitis. A Cohort Study.
    Nukarinen E; Lindström O; Kuuliala K; Kylänpää L; Pettilä V; Puolakkainen P; Kuuliala A; Hämäläinen M; Moilanen E; Repo H; Hästbacka J
    PLoS One; 2016; 11(8):e0161480. PubMed ID: 27561093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
    Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
    Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
    Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
    Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of thalassemia major and gingival inflammation: A pilot study.
    Gümüş P; Kahraman-Çeneli S; Akcali A; Sorsa T; Tervahartiala T; Buduneli N; Özçaka Ö
    Arch Oral Biol; 2016 Apr; 64():80-4. PubMed ID: 26799499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer.
    Sirniö P; Tuomisto A; Tervahartiala T; Sorsa T; Klintrup K; Karhu T; Herzig KH; Mäkelä J; Karttunen TJ; Salo T; Mäkinen MJ; Väyrynen JP
    Br J Cancer; 2018 Jul; 119(2):213-219. PubMed ID: 29808017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High serum MMP-14 predicts worse survival in gastric cancer.
    Kasurinen A; Tervahartiala T; Laitinen A; Kokkola A; Sorsa T; Böckelman C; Haglund C
    PLoS One; 2018; 13(12):e0208800. PubMed ID: 30532247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periodontal health and serum, saliva matrix metalloproteinases in patients with mild chronic obstructive pulmonary disease.
    Yıldırım E; Kormi I; Başoğlu ÖK; Gürgün A; Kaval B; Sorsa T; Buduneli N
    J Periodontal Res; 2013 Jun; 48(3):269-75. PubMed ID: 22967248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines.
    Lauhio A; Hästbacka J; Pettilä V; Tervahartiala T; Karlsson S; Varpula T; Varpula M; Ruokonen E; Sorsa T; Kolho E
    Pharmacol Res; 2011 Dec; 64(6):590-4. PubMed ID: 21742038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
    Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
    Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2011 Sep; 20(3):287-91. PubMed ID: 21961097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.